DK1706102T3 - Farmaceutiske formuleringer indeholdende metformin og et fibrat samt fremgangsmåder til opnåelse deraf - Google Patents

Farmaceutiske formuleringer indeholdende metformin og et fibrat samt fremgangsmåder til opnåelse deraf

Info

Publication number
DK1706102T3
DK1706102T3 DK05715343.9T DK05715343T DK1706102T3 DK 1706102 T3 DK1706102 T3 DK 1706102T3 DK 05715343 T DK05715343 T DK 05715343T DK 1706102 T3 DK1706102 T3 DK 1706102T3
Authority
DK
Denmark
Prior art keywords
fibrate
obtaining
methods
well
pharmaceutical formulations
Prior art date
Application number
DK05715343.9T
Other languages
English (en)
Inventor
Carthy Leonard Mc
Gordon Dawson
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Application granted granted Critical
Publication of DK1706102T3 publication Critical patent/DK1706102T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05715343.9T 2004-01-23 2005-01-24 Farmaceutiske formuleringer indeholdende metformin og et fibrat samt fremgangsmåder til opnåelse deraf DK1706102T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04001499A EP1559419A1 (en) 2004-01-23 2004-01-23 Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
PCT/EP2005/001524 WO2005070396A1 (en) 2004-01-23 2005-01-24 Pharmaceutical formulations comprising metformin and a fibrate, and processes for obtaining them

Publications (1)

Publication Number Publication Date
DK1706102T3 true DK1706102T3 (da) 2011-12-19

Family

ID=34639372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05715343.9T DK1706102T3 (da) 2004-01-23 2005-01-24 Farmaceutiske formuleringer indeholdende metformin og et fibrat samt fremgangsmåder til opnåelse deraf

Country Status (21)

Country Link
US (2) US20080020046A1 (da)
EP (2) EP1559419A1 (da)
JP (1) JP4740881B2 (da)
CN (1) CN100531722C (da)
AT (1) ATE521338T1 (da)
AU (1) AU2005205930B2 (da)
BR (1) BRPI0507022A (da)
CA (1) CA2553967A1 (da)
CY (1) CY1111961T1 (da)
DK (1) DK1706102T3 (da)
EA (1) EA009773B1 (da)
ES (1) ES2370948T3 (da)
IL (1) IL176903A0 (da)
MA (1) MA28353A1 (da)
NO (1) NO20062792L (da)
PL (1) PL1706102T3 (da)
PT (1) PT1706102E (da)
SI (1) SI1706102T1 (da)
TN (1) TNSN06222A1 (da)
WO (1) WO2005070396A1 (da)
ZA (1) ZA200605882B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
WO2007143099A2 (en) * 2006-06-01 2007-12-13 Sobel Burton E Methods for inhibiting cardiac pai-1
EA200900531A1 (ru) * 2006-10-12 2009-12-30 Эббот Лаборейторис Фармацевтические составы
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
WO2011154013A1 (en) * 2010-06-10 2011-12-15 Lifecycle Pharma A/S Pharmaceutical composition comprising fenofibric acid
BR112013007469B1 (pt) * 2010-09-21 2020-03-31 Intekrin Therapeutics, Inc. Composições farmacêuticas antidiabéticas sólidas, seu uso e método de preparação, método para preparar um produto de granulação e composição precursora farmacêutica
WO2013064853A1 (en) * 2011-11-05 2013-05-10 Lupin Atlantis Holdings, S.A. Reduced dose oral pharmaceutical compositions of fenofibrate
WO2013077821A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Homogeneous biguanide composition
WO2014091318A1 (en) * 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
CN107531900A (zh) * 2015-03-06 2018-01-02 北卡罗来纳-查佩尔山大学 聚合物二甲双胍和其作为治疗剂和作为递送载体的用途
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy
EP4188352A1 (en) * 2020-07-31 2023-06-07 KRKA, d.d., Novo mesto Pharmaceutical formulation of metformin having low content of dimethylamine
WO2023234935A1 (en) * 2022-05-31 2023-12-07 Venkor Corporation Bonded microparticulates preparation and applications thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907792A (en) * 1969-01-31 1975-09-23 Andre Mieville Phenoxy-alkyl-carboxylic acid derivatives and the preparation thereof
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4499289A (en) * 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
KR100620935B1 (ko) * 1998-03-19 2006-09-13 브리스톨-마이어스스퀴브컴파니 용해도가 높은 약물에 대한 2상 서방성 전달 시스템과 방법
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides

Also Published As

Publication number Publication date
EA009773B1 (ru) 2008-04-28
NO20062792L (no) 2006-09-25
CN100531722C (zh) 2009-08-26
US20110305733A1 (en) 2011-12-15
JP2007518773A (ja) 2007-07-12
CY1111961T1 (el) 2015-11-04
CA2553967A1 (en) 2005-08-04
ES2370948T3 (es) 2011-12-26
EP1706102A1 (en) 2006-10-04
BRPI0507022A (pt) 2007-06-05
JP4740881B2 (ja) 2011-08-03
AU2005205930A1 (en) 2005-08-04
PT1706102E (pt) 2011-12-16
CN1909890A (zh) 2007-02-07
MA28353A1 (fr) 2006-12-01
TNSN06222A1 (en) 2007-12-03
EA200601215A1 (ru) 2007-02-27
IL176903A0 (en) 2006-12-10
AU2005205930B2 (en) 2007-09-20
US20080020046A1 (en) 2008-01-24
ATE521338T1 (de) 2011-09-15
EP1559419A1 (en) 2005-08-03
EP1706102B1 (en) 2011-08-24
PL1706102T3 (pl) 2012-01-31
SI1706102T1 (sl) 2011-12-30
WO2005070396A1 (en) 2005-08-04
ZA200605882B (en) 2009-03-25

Similar Documents

Publication Publication Date Title
DK1706102T3 (da) Farmaceutiske formuleringer indeholdende metformin og et fibrat samt fremgangsmåder til opnåelse deraf
WO2006025979A3 (en) Modulators of nuclear receptors
GEP20074133B (en) New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it
SE0301373D0 (sv) Novel compounds
TW200738666A (en) Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
UY29344A1 (es) Anticuerpos antiamiloides humanizados
EA200700255A1 (ru) Новый карбамилированный еро и способ его получения
DE60317159D1 (de) Durch Michael-Additionsreaktion härtbare Zusammensetzung
MX2009005461A (es) N-oxidos de analogos de 4,5-epoxi-morfinano.
CO6280399A2 (es) Peptidil nitrilos y uso de los mismos como inhibidores de peptidil peptidasa i
TW200738641A (en) Pyrazole based LXR modulators
SE0303180D0 (sv) Novel compounds
DE602004006618D1 (de) Azaindolverbindungen als kinaseinhibitoren
SE0302232D0 (sv) Novel Compounds
TW200510301A (en) Novel compounds
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
SE0301010D0 (sv) Novel compounds
SE0202241D0 (sv) Novel Compounds
MY144482A (en) Biphenyl compounds useful as muscarinic receptor antagonists
SE0301009D0 (sv) Novel compounds
HK1113790A1 (en) Selurampanel
ZA200900890B (en) Purification process of Montelukast and its amine salts
PA8663901A1 (es) Derivados del (1,5-difenil-1h-pirazol-3-il)oxadiazol, su prepararacion y su aplicacion en terapéutica
GT200300010A (es) Esteres hidroxamato del acido n-(4-fenil sustituido)-antranilico
HK1159614A1 (en) Caspase inhibitors and uses thereof